Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration

Arch Ophthalmol. 2012 Jun;130(6):794-5. doi: 10.1001/archophthalmol.2011.2480.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Blindness / diagnosis
  • Blindness / drug therapy
  • Blindness / epidemiology*
  • Female
  • Humans
  • Laser Coagulation
  • Male
  • Photochemotherapy
  • Prevalence
  • Retrospective Studies
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vision, Low / diagnosis
  • Vision, Low / drug therapy
  • Vision, Low / epidemiology*
  • Visual Acuity / physiology
  • Visually Impaired Persons / statistics & numerical data*
  • Wet Macular Degeneration / diagnosis
  • Wet Macular Degeneration / drug therapy*

Substances

  • Angiogenesis Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A